Y Intercept Hong Kong Ltd Purchases New Shares in Galectin Therapeutics Inc. (NASDAQ:GALT)

Y Intercept Hong Kong Ltd acquired a new stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 235,192 shares of the company's stock, valued at approximately $287,000. Y Intercept Hong Kong Ltd owned approximately 0.37% of Galectin Therapeutics at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. HighTower Advisors LLC acquired a new stake in Galectin Therapeutics in the 4th quarter valued at approximately $29,000. Two Sigma Securities LLC acquired a new stake in Galectin Therapeutics in the 4th quarter valued at approximately $37,000. Bank of America Corp DE increased its position in shares of Galectin Therapeutics by 101.4% during the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company's stock worth $49,000 after purchasing an additional 19,316 shares during the last quarter. Vivaldi Capital Management LP increased its position in shares of Galectin Therapeutics by 89.9% during the 4th quarter. Vivaldi Capital Management LP now owns 45,628 shares of the company's stock worth $56,000 after purchasing an additional 21,596 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Galectin Therapeutics by 46.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 51,510 shares of the company's stock worth $66,000 after purchasing an additional 16,412 shares during the last quarter. Institutional investors own 11.68% of the company's stock.

Analyst Upgrades and Downgrades

GALT has been the topic of several recent analyst reports. HC Wainwright initiated coverage on Galectin Therapeutics in a research report on Tuesday, June 17th. They set a "buy" rating and a $6.00 price target on the stock. Wall Street Zen raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st.

Galectin Therapeutics Stock Up 0.3%

Shares of GALT stock traded up $0.01 during trading on Friday, reaching $3.65. 294,511 shares of the company's stock were exchanged, compared to its average volume of 424,224. The stock has a market capitalization of $231.01 million, a PE ratio of -5.07 and a beta of 0.70. Galectin Therapeutics Inc. has a twelve month low of $0.73 and a twelve month high of $3.90. The firm's fifty day moving average price is $2.20 and its 200-day moving average price is $1.67.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.05. As a group, analysts anticipate that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.